67 related articles for article (PubMed ID: 440651)
1. The prognostic value of serum immunosuppressive effect in patients with ovarian cancer.
Ueda K; Toyokawa M; Nakamori H; Sako H; Umesaki N; Nakade J; Lee T; Sugawa T
Obstet Gynecol; 1979 Apr; 53(4):480-3. PubMed ID: 440651
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive effect of serum in patients with ovarian carcinoma.
Ueda K; Toyokawa M; Nakamori H; Sako H; Umesaki N; Nakade J; Lee T; Sugawa T
Obstet Gynecol; 1978 Feb; 51(2):225-8. PubMed ID: 304546
[TBL] [Abstract][Full Text] [Related]
3. The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma.
Kikuchi Y; Oomori K; Kizawa I; Kato K
Jpn J Clin Oncol; 1985 Jun; 15(2):377-83. PubMed ID: 3839542
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
[TBL] [Abstract][Full Text] [Related]
5. [Controlled study of unspecific cellular immunity in cancer patients].
Dominioni L; Dionigi R; Prati U; Cividini F; Cincera M; Pavesi L; Della Cuna GR
Minerva Med; 1981 Mar; 72(12):733-40. PubMed ID: 6971418
[TBL] [Abstract][Full Text] [Related]
6. Characterization of peripheral blood and ovarian cancer-infiltrating lymphocytes: effect of HIV infection on phenotypic expression and proliferative response.
Guidozzi F; Reddy S; Wadee A
Gynecol Oncol; 1994 May; 53(2):251-5. PubMed ID: 8188090
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.
Makar AP; Kristensen GB; Kaern J; Børmer OP; Abeler VM; Tropé CG
Obstet Gynecol; 1992 Jun; 79(6):1002-10. PubMed ID: 1579296
[TBL] [Abstract][Full Text] [Related]
8. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T
Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068
[TBL] [Abstract][Full Text] [Related]
9. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the lymphocyte responses to phytohemagglutinin (PHA) using microquantitative peripheral whole blood culture technique in the management of patients with ovarian cancer (author's transl)].
Takizawa K; Kawabata M; Kawana T; Shiromizu K; Sakamoto S
Nihon Gan Chiryo Gakkai Shi; 1981 Oct; 16(6):1239-47. PubMed ID: 7334260
[No Abstract] [Full Text] [Related]
11. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1993 Apr; 49(1):3-7. PubMed ID: 8482556
[TBL] [Abstract][Full Text] [Related]
12. Serum-mediated immunosuppression: a possible tumor marker in patients with ovarian carcinoma.
Onsrud M
Gynecol Oncol; 1985 May; 21(1):94-100. PubMed ID: 3988128
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response.
Vaccarello L; Rubin SC; Vlamis V; Wong G; Jones WB; Lewis JL; Hoskins WJ
Gynecol Oncol; 1995 Apr; 57(1):61-5. PubMed ID: 7705701
[TBL] [Abstract][Full Text] [Related]
14. Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience.
Le T; Krepart GV; Lotocki RJ; Heywood MS
Gynecol Oncol; 1997 May; 65(2):237-40. PubMed ID: 9159331
[TBL] [Abstract][Full Text] [Related]
15. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
[TBL] [Abstract][Full Text] [Related]
16. Serial determinations of aminoterminal propeptide of type III procollagen (PIIINP) and prognosis in ovarian cancer; comparison to CA125.
Simojoki M; Santala M; Risteli J; Risteli L; Kauppila A
Anticancer Res; 2000; 20(6C):4655-60. PubMed ID: 11205196
[TBL] [Abstract][Full Text] [Related]
17. [Secondary cytoreductions in the treatment of ovarian cancers].
Zylberberg B; Dormont D; Janklewicz S; Daraï E; Madelenat P; Antoine JM
Gynecol Obstet Fertil; 2000 Feb; 28(2):127-36. PubMed ID: 10758587
[TBL] [Abstract][Full Text] [Related]
18. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
[TBL] [Abstract][Full Text] [Related]
19. [Biochemical estimation of post-treatment surveillance for ovarian cancer: simultaneous determination of serum C-reactive protein level and lymphocyte responses to phytohemagglutinin].
Takizawa K; Kawana T; Kawabata M; Sakamoto S
Nihon Gan Chiryo Gakkai Shi; 1982 Feb; 17(1):22-30. PubMed ID: 7130784
[No Abstract] [Full Text] [Related]
20. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1993 Apr; 49(1):73-9. PubMed ID: 8482563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
